Back to News
Market Impact: 0.48
Xenon Pharma Tumbles On Azetukalner Psychiatry Trial Enrollment Pause; Files Focal Seizure NDA
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Xenon Pharmaceuticals shares plunged more than 25% after hours after the company voluntarily paused new patient enrollment in ongoing Phase 3 studies of azetukalner for major depressive disorder. The enrollment halt introduces material clinical-development and regulatory uncertainty for the neuroscience-focused biotech's key late-stage program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.72
Ticker Sentiment
XENE-0.90
More News
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- New Apple CEO John Ternus chalks up some early wins, but the honeymoon is over
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Oracle files to sell $20 billion in new stock, bonds to finance AI buildout